Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Poster Session Abstracts

Abstract P5-09-07: Identification of resistance-specific gene expression signatures in a breast cancer patient-derived xenograft with acquired resistance to different endocrine therapies

PH Cottu, I Bièche, P de la Grange, D Gentien, F Assayag, A Thuleau, R El-Botty, S Chateau-Joubert, M Huerre, R Hatem, S Richon, K Slimane and E Marangoni
PH Cottu
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I Bièche
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P de la Grange
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D Gentien
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Assayag
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Thuleau
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R El-Botty
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Chateau-Joubert
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Huerre
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Hatem
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Richon
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Slimane
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Marangoni
Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.SABCS13-P5-09-07 Published December 2013
  • Article
  • Info & Metrics
Loading
Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX

Abstract

Background:

Acquired resistance to endocrine treatments (ET) occurs in more than 70% of cases of luminal breast cancer (LBC). We used patient derived xenografts (PDX) models of LBC to study molecular changes associated with acquired resistance to different ET modalities.

Methods:

A PDX model of LBC, established from an early stage BRCA2-mutated breast cancer, was treated with different ET (tamoxifen, fulvestrant, oophorectomy and letrozole) during several months. Tumors escaping to therapies were re-engrafted and maintained under therapy. ET-resistant and parental hormono-responders tumors were analyzed with immunohistochemistry (IHC), RT-PCR and Affymetrix Gene Expression Arrays. Hormono-resistant tumors were additionally studied for their in vivo response to ET, mTOR and PARP inhibitors.

Results:

From the initially ET sensitive HBCx22 xenograft model (Cottu, BCRT 2012) two resistant models were obtained respectively to tamoxifen (HBCx22-TamR) and to estrogen deprivation (HBCx22-OvaR). Unsupervised clustering of gene expression showed a clear cut separation between parental, TamR and OvaR tumors. Genes differentially expressed in TamR and OvaR tumors compared to parental HBCx22 were only partially overlapping. Up-Regulated genes in both TamR and OvaR tumors (n = 302) were involved in response to wounding, nucleotide metabolism, immune system, adhesion and cell growth. Biological Processes (BP) specifically deregulated in OvaR tumors (n = 380) included embryonic development, antigen presentation, amino acid and lipid metabolism. The top BP specifically regulated in TamR tumors (n = 1059) were response to estrogen and steroid hormones, TGF-b signaling, hypoxia, regulation of cell proliferation, with several strongly up-regulated genes of the histone clusters 1 and 3. Ingenuity Transcription Factor Analysis predicted activation of NFKB, SP1, AP-1 and JUN, and inhibition of ESR1. RT-PCR and IHC analyses confirmed the down regulation of ER controlled genes in the TamR tumors. Expression of ER co-regulators determined by RT-PCR showed that GREB1 was strongly reduced in TamR, while PBX1, GATA3 and FOXA1 were inhibited in OvaR. IHC analysis showed a loss of PTEN expression in HBCx22, with high levels of p-AKT and p-RPS6 in both parental and TamR and OvaR tumors. In vivo ET showed that the TamR xenograft was resistant to all modalities of ET, while OvaR was resistant to estrogen deprivation while retaining some sensitivity to tamoxifen and fulvestrant. Treatment with the mTOR inhibitor RAD001 arrested tumor growth but did not show any additive effect when combined to ET in TamR or OvaR tumors. Conversely, the combination of RAD001 with Olaparib was highly synergistic and induced complete tumor response in 70% of mice.

Conclusions:

According to the therapeutic selection, tumors derived from a PDX model of ER+ breast cancer show specific resistance patterns and gene expression profiles including disruption in the ER transcriptional program. The analysis of additional resistant tumors established from a second ER+ PDX will be presented at the meeting.

Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-09-07.

Previous
Back to top
Cancer Research: 73 (24 Supplement)
December 2013
Volume 73, Issue 24 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract P5-09-07: Identification of resistance-specific gene expression signatures in a breast cancer patient-derived xenograft with acquired resistance to different endocrine therapies
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract P5-09-07: Identification of resistance-specific gene expression signatures in a breast cancer patient-derived xenograft with acquired resistance to different endocrine therapies
PH Cottu, I Bièche, P de la Grange, D Gentien, F Assayag, A Thuleau, R El-Botty, S Chateau-Joubert, M Huerre, R Hatem, S Richon, K Slimane and E Marangoni
Cancer Res December 15 2013 (73) (24 Supplement) P5-09-07; DOI: 10.1158/0008-5472.SABCS13-P5-09-07

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract P5-09-07: Identification of resistance-specific gene expression signatures in a breast cancer patient-derived xenograft with acquired resistance to different endocrine therapies
PH Cottu, I Bièche, P de la Grange, D Gentien, F Assayag, A Thuleau, R El-Botty, S Chateau-Joubert, M Huerre, R Hatem, S Richon, K Slimane and E Marangoni
Cancer Res December 15 2013 (73) (24 Supplement) P5-09-07; DOI: 10.1158/0008-5472.SABCS13-P5-09-07
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Poster Session Abstracts

  • Abstract P6-08-04: National trends in mastectomy for operable breast cancers treated with neoadjuvant chemotherapy
  • Abstract P6-15-12: A functional approach to the molecular basis of neoadjuvant treatment response in breast cancer
  • Abstract P6-14-06: Oral etoposide (VP-16) in heavily pre-treated metastatic breast cancer: A multicenter national observational study
Show more 3

Poster Session 5: Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance

  • Abstract P5-09-12: Novel role of proto-oncogene PELP1 in A-NHEJ pathway of double strand break repair: Implications for treatment of hormonal therapy resistance
  • Abstract P5-09-17: Prognostic significance of progesterone receptor in hormonal receptor-positive breast cancer: Association with endocrine resistance
  • Abstract P5-09-09: ESRP1 and ESRP2 expression in tamoxifen resistance
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement